惠泰医疗：四季度毛利率预计与三季度相近，多产品有望上量

Core Viewpoint - The company expects its gross margin in Q4 to remain stable compared to Q3, with no significant changes in product sales structure [1] Group 1: Gross Margin Expectations - The company anticipates that the gross margin for Q4 will be similar to that of Q3, primarily due to a lack of significant changes in the sales structure of products [1] Group 2: Product Launches - Expected high-value products for Q4 include electrophysiology PFA products, peripheral balloons and microcatheters, peripheral dissolvable coils, second-generation coronary thin-walled sheaths, and hydrophilic-coated contrast tubes [1]